AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03673137 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Irreversible electroporation
Description: During the IRE process, we employed a CT scanner and an ultrasound system to guide percutaneous insertion of the electrode probes (one main electrode and one to three standard electrodes were used per treatment). The electrode number, electrode-insertion mode and intraoperative parameters were decided upon during pretreatment planning. The IRE parameters were visually simulated in the pulse generator and set up as follows: energy was applied at 1500 V/cm for 90 ms/pulse for a total of 7-9 pulses. After an initial testing pulse train was discharged to establish the best voltage value, the remaining 80 pulses were completed in 1-2 minutes. After ablation, we confirmed completion of IRE by measuring real-time resistance or current changes, in addition to intraoperative ultrasound and CT.
Study NCT03673137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine hydrochloride (Qilu pharmaceutical \[Hainan\] Co., Ltd. Haikou, China\] was administered by intravenous infusion at a dose of 1000 mg/m2.
Study NCT03673137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine hydrochloride (Qilu pharmaceutical \[Hainan\] Co., Ltd. Haikou, China\] was administered by intravenous infusion at a dose of 1000 mg/m2.
Study NCT02396238 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Celution Device
Description: ADRCs prepared using the investigational Celution Device
Study NCT02396238 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00294190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Topotecan 6mg/m2 IV weekly x 6 consecutive weeks followed by a 2 week break.
Study NCT03985293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 matching placebo tablets taken twice a day (BID)
Study NCT03985293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961
Description: Participants will be randomized to one of 5 active doses (2.5, 10, 40, 80, or 120 mg), taking 4 tablets twice daily for 16 weeks.
Study NCT02788734 — intervention group
Intervention type: OTHER
Intervention: Web-based survey
Description: This study protocol consists of one anonymous survey. Each participant can complete only one survey. The survey will take approximately 25 minutes to complete. The survey is designed to identify items that best reflect the symptom severity and functional status in patients with CTS and CMT. A unique link to the survey will be included in an email invitation distributed to all adult CMT or HNPP patients self-registered in the RDCRN INC Contact Registry. Upon clicking the link, the participant will be directed to the IRB-approved online consent form. Upon providing consent, the participant will be directed to the online survey.
Study NCT01749891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALG 1001
Description: Patients who will receive three, monthly intravitreal injections of 1.5mg, 2.5mg ,or 4.0 /50μl of ALG-1001 in 0.05cc in isotonic saline solution.
Study NCT01900925 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prescriptive Hip Exercises and Manual Therapy techniques
Description: 1) Clam Abduction exercises in sidelying, 2) Hip extension in quadruped, 3) a unilateral bridge,and; 1) anterior to posterior mobilization of the hip with distraction, 2) long axis distraction of the hip and 3) posterior-anterior mobilization of the hip in prone
Study NCT01900925 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pragmatic low back pain treatment
Description: 1. advise to stay active,~2. discourage bed rest,~3. appropriate medication use,~4. reassurance.~5. Short term use of manipulation/medication,~6. supervised exercise,~7. cognitive behavioral therapy,~8. multidisciplinary treatment,~9. termination of use of modalities.
Study NCT01900925 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pragmatic low back pain treatment
Description: 1. advise to stay active,~2. discourage bed rest,~3. appropriate medication use,~4. reassurance.~5. Short term use of manipulation/medication,~6. supervised exercise,~7. cognitive behavioral therapy,~8. multidisciplinary treatment,~9. termination of use of modalities.
Study NCT01922024 — intervention group
Intervention type: DEVICE
Intervention: LRT55 Testing
Description: Testing on the Unyvero LRT55
Study NCT02470728 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New Clinical Pathway
Study NCT04522037 — intervention group
Intervention type: OTHER
Intervention: No intervention / Compare the difference in respiratory rate between H0 and H12 of the initiation of morphine between the control and interventional groups
Description: Respiratory rate is analyzed with the scope (approved by the French national medical authorities)
Study NCT04495088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX (neoadjuvant)
Description: neoadjuvant application Folinic acid: 400 mg/m2, 2h i.v., on day 1 Oxaliplatin: 85 mg/m2, 2-6h i.v., on day 1 5-FU: 2400 mg/m2, 46-48h i.v., on day 1. Cycles are repeated on day 15. A total of 6 cycles are administered.
Study NCT03930615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir
Description: LET tablet or intravenous infusion at a total daily dose of 240 mg (when given with cyclosporin A) or 480 mg (when given alone).
Study NCT03930615 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered as tablets matched to LET or as inactive (saline or dextrose) intravenous infusion.
Study NCT04495088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX (neoadjuvant)
Description: neoadjuvant application Capecitabine: 1,000 mg/m2 bid, po, on days 1-14 Oxaliplatin: 130 mg/m2, 2-6h i.v. day 1 Cycles are repeated on day 22. A total of 4 cycles are administered.
Study NCT04495088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX (adjuvant)
Description: adjuvant application Folinic acid: 400 mg/m2, 2h i.v., on day 1 Oxaliplatin: 85 mg/m2, 2-6h i.v., on day 1 5-FU: 2400 mg/m2, 46-48h i.v., on day 1. Cycles are repeated on day 15. A total of 6 cycles are administered.
Study NCT04495088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XELOX (adjuvant)
Description: adjuvant application Capecitabine: 1,000 mg/m2 bid, po, on days 1-14 Oxaliplatin: 130 mg/m2, 2-6h i.v. day 1 Cycles are repeated on day 22. A total of 4 cycles are administered.
Study NCT04495088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine (adjuvant)
Description: adjuvant application Capecitabine: 1,250 mg/m2 bid, po, on days 1-14 Cycles are repeated on day 22. A total of 8 cycles are administered.
Study NCT04495088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: infusional 5-FU/FA AIO regimen (adjuvant)
Description: adjuvant application Folinic acid 2h i.v. 500 mg/m² 5-FU 2,600mg/m² (24h infusion) Days 1, 8, 15, 22, 29, 36; cycle is repeated day 57 (representing one cycle); a total of 3 cycles should be administered.
Study NCT04495088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: infusional 5-FU/FA de Gramont (adjuvant)
Description: adjuvant application Folinic acid 2h i.v. 200 mg/m² days 1 and 2 5-FU 400mg/m² bolus followed by 600mg/m² 22h infusion days 1 and 2 The cycle is repeated day 15; a total of 12 cycles should be administered.
Study NCT02409862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin Spray
Description: This group will receive the single dose of 24 IU oxytocin, self-administered intranasally (IN). Prior to administration a saliva sampling will be done. Afterwards, they will participate in the Choices Study during EEG and eye tracking recording.
Study NCT02409862 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Spray
Description: This group will receive the single dose of 24 IU placebo, self-administered intranasally (IN). Prior to administration a saliva sampling will be done. Afterwards, they will participate in the Choices Study during EEG and eye tracking recording.
Study NCT03843307 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Avazzia Tennant Biomodulator® PRO
Description: High-voltage pulsed current (HVPC) electrical stimulation with Reactions and BEST™ (Bio-Electric Stimulation Technology) microcurrent that measure and change with tissue electrical characteristics.
Study NCT04185259 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: The investigators will apply two Ashi points (the two most severe tender points in the most sensitive area over the anteromedial aspect of the heels), Chengshan (BL57), Taixi (KI3) and Kunlun (BL60) in this trial. With the patient in a prone position, the local skin will be routinely sterilized followed by a 10mm diameter and 5mm thick sterile adhesive pad pasting onto each selected acupoint. Ashi points will be perpendicularly inserted through the pad to the plantar fascia layer with a depth of approximately 15-20mm depending on the location. BL57, KI3 and BL60 will be punched perpendicularly 10-15mm deep into the skin through the pad. All needles except Ashi points will be manually stimulated by small, equal manipulations of lifting, thrusting, twirling and rotating to achieve De qi. Needles will be retained for 30 minutes per treatment. During each treatment, every needle will be manipulated three times every 10 minutes.
Study NCT03306342 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOL implantation experimental
Description: Implantation of trifocal IOL POD F GF consisting of hydrophobic material
Study NCT00749931 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MarginProbe
Description: Device use to assess margin status of the excised specimen surface.
Study NCT00014235 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo PBSCT
Study NCT04185259 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: Sham Ashi (0.5 cun away from Ashi, one 'cun' is equivalent to the greatest width of the individual patients' thumb, \~1.5 cm), sham BL57 (0.5 cun lateral to true BL57 horizontally), sham KI3 (midway between true KI3 and heel tendon) and sham BL60 (midway between true BL60 and heel tendon) will be used. Treatment protocol will be similar to that of the acupuncture group. The Hwato-brand disposable blunt-tipped needles (size 0.30 × 25 mm) will be inserted at sham points through adhesive pads to the skin without skin penetration. The needles will then be lifted, thrusted, twirled, and rotated evenly three times every ten minutes. No specific de qi response will be elicited.
Study NCT04602208 — intervention group
Intervention type: PROCEDURE
Intervention: Retrospectively review of medical data in patients treated by focal HIFU for primary localized prostate cancer
Description: This study concern the patients with localized prostate cancer treated by Focal HIFU for low or intermediate risk disease. Three surgeons experienced in HIFU performed the procedures. Patients were treated with the Ablatherm device \[EDAP TMS S.A., Vaulx-en-Velin, France\] until July 2013 and then with the Focal-One device \[EDAP TMS S.A.\]. The data of all the patients treated between November 2009 to December 2016, at Edouard Herriot Hospital (Lyon, France), were prospectively maintain within a central database and retrospectively reviewed. The study primary outcome was retreatment-free survival (RFS) defined as any additional further treatment: local (FT/PGA for in-field or out-of-field recurrences or radical prostatectomy or external beam radiotherapy or whole gland HIFU) or systemic salvage treatment, a positive biopsy revealing PCa with an ISUP grade≥ 2 in nontreated patients, PCa metastasis or PCa specific death. The adverse events and functional outcomes were also evaluated.
Study NCT00014235 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo PBSCT
Study NCT00014235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given PO or IV
Study NCT00749931 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumpectomy
Description: Standard of care lumpectomy procedure
Study NCT00749931 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumpectomy
Description: Standard of care lumpectomy procedure
Study NCT00014235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given IV or PO
Study NCT04216082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib is a oral small molecule receptor tyrosine kinases inhibitor with the potency of inhibiting tumor angiogenesis as well as cell proliferation simultaneously and have been approved to treat advanced non-small cell lung cancer (NSCLC) in China. Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
Study NCT01969201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urofollitrophin
Study NCT01969201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitrophin alpha
Study NCT00879762 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMVAMUNE® High Dose
Description: IMVAMUNE® Vaccinia Vaccine, undiluted, delivered by subcutaneous route on Day 0 at high dose 5×10\^8 TCID50 (5×10\^8 TCID50 per 1.0 mL dose - administered as 2 x 0.5 mL.
Study NCT00879762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.5 mL injection of saline placebo administered with vaccine on Day 0 (Group B) or single saline placebo dose (single 0.5 mL injection) on Day 28 (Group A).
Study NCT00879762 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 0.5 mL injection of saline placebo administered with vaccine on Day 0 (Group B) or single saline placebo dose (single 0.5 mL injection) on Day 28 (Group A).
Study NCT00879762 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IMVAMUNE® Standard Dose
Description: IMVAMUNE® Vaccinia Vaccine delivered by subcutaneous (SC) route on Day 0 and 28 at standard dose (diluted with saline by study pharmacist to (1×10\^8 tissue culture infectious dose 50 \[TCID50\] per 0.5 mL dose)
Study NCT02351206 — intervention group
Intervention type: RADIATION
Intervention: x-ray, MRI
Study NCT00285012 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1mg (placebo) by mouth twice daily for 12 weeks (first week is up titration schedule---0.5mg once daily for 3 days, 0.5mg twice daily for 4 days)
Study NCT00285012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline Tartarate
Description: 1 mg by mouth twice daily for 12 weeks (first week is up titration schedule---0.5mg once daily for 3 days, 0.5mg twice daily for 4 days)
Study NCT02424851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: 1.3 mg/m2 subcutaneously\* days 1, 4, 8 and 11 of each cycle. Number of cycles: Four 21 day cycles (participants not suitable for ASCT (autologous stem cell transplant) will continue up to 6 cycles on the treatment regimen to which they were randomised).~\*intravenous infusion available in case of patient intolerance to subcutaneous bortezomib
Study NCT02424851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: 100 mg daily orally, preferably at night, days 1-21 of each cycle. Four 21 day cycles (participants not suitable for ASCT will continue up to 6 cycles on the treatment regimen to which they were randomised)
Study NCT02424851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: 60 mg/m2 i.v. days 1 and 8 of each cycle. Four 21 day cycles (participants not suitable for ASCT will continue up to 6 cycles on the treatment regimen to which they were randomised)
Study NCT02424851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 40mg orally days 1-2, 4-5, 8-9 and 11-12 of each cycle
Study NCT04434534 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hipocaloric Diet with Açaí Juçara
Description: Daily consumption of Açaí Juçara pulp (200g) and nutritional adequacy of meals in individualized diet plans calculated for each participant.
Study NCT04434534 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hipocaloric Diet
Description: Nutritional adequacy of meals in individualized diet plans calculated for each participant.
Study NCT03949946 — intervention group
Intervention type: PROCEDURE
Intervention: Magnetic resonance imaging (MRI)
Description: MRI scan uses radio waves in a magnetic field to obtain images of the breast. It is non-invasive and participants will not be exposed to harmful radiation. An image contrast agent will be used to enhance image clarity. Participants will be scanned lying face-down on a specially-designed bed and ear protectors will be provided to screen out background noise.
Study NCT00534690 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: One-Lung ventilation
Description: Low Vt, High PEP
Study NCT00534690 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: One-Llung ventilation
Description: High Vt, low PEP
Study NCT01721941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase I Dose level -1
Description: The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
Study NCT01721941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase I dose level 1
Description: The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
Study NCT01721941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase I Dose level 2
Description: The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
Study NCT00772551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir and ezetimibe
Description: Group 1: raltegravir 400 mg orally twice daily for 10 days followed by 10 days of raltegravir 400 mg twice daily and ezetimibe 10 mg orally once daily for 10 days followed by a 10 days wash out period and ezetimibe 10 mg once daily for 10 days
Study NCT00772551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe and raltegravir
Description: Group2: ezetimibe 10 mg orally once daily for 10 days followed by ezetimibe 10 mg and raltegravir 400 mg orally twice daily for 10 days followed by a 10 days wash out period and raltegravir 400 mg twice daily for 10 days
Study NCT04121325 — intervention group
Intervention type: DEVICE
Intervention: Enterra
Description: To measure validated and subjective pain scores among patients with an existing GES device, and who have a trial of new settings directed at abdominal pain and compare their pain scores to each patient baseline symptoms, done with their previous GES settings.
Study NCT03957434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Education, pelvic floor muscle exercises with biofeedback and home exercises.
Study NCT03992807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A patient decision aid
Description: Potential participants receive a printed decision aid booklet with information about cataract surgery choice, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks and 1 year.
Study NCT03992807 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A usual education booklet
Description: Potential participants receive a usual booklet about cataract and cataract surgery, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks and 1 year.
Study NCT03550924 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: low flow passive oxygenation
Description: low flow passive oxygenation during laryngoscopy with 10l/min oxygen via standard nasal prongs
Study NCT03550924 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high flow passive oxygenation
Description: high flow passive oxygenation during laryngoscopy with 120l/min oxygen via THRIVE system
Study NCT04361526 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cytokine Adsorption
Description: Cytokine adsorption will be performed through a venous hemodialysis catheter, preferably jugular or femoral. The filtration system will be established with a cytokine adsorption cartridge in an hemoperfusion system using a blood flow rate of 150 - 200 ml/min. Adsorbent therapy will last 72 hours, changing cartridges every 24 hours. Prior to start, heparinization will be stablished by a 1mg/Kg iv Na heparin bolus plus iv perfusion. Activated Partial Thromboplastin Time (aPTT) control will be performed every 6 hours, with a goal range between 60 and 80 seconds.
Study NCT02569671 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Straumann Bone Level Tapered Implant - Immediate Placement
Description: Immediate placement of a Straumann Bone Level Tapered Dental Implant for replacement of a singe tooth.
Study NCT02569671 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Straumann Bone Level Tapered Implant - Delayed Placement
Description: Delayed placement of a Straumann Bone Level Tapered Dental Implant for replacement of a singe tooth.
Study NCT02923518 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Observational study without any intervention described under intervention type
Study NCT01161758 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Passive cervical mobilisation
Description: Passive cervical mobilization which involved an oscillatory grade III unilateral postero-anterior mobilization applied to the left C5/C6 segment. The mobilization consisted of 3 periods of 1 minute applications with a resting period of 1 minute in between.